MYOSITIS
Clinical trials for MYOSITIS explained in plain language.
Never miss a new study
Get alerted when new MYOSITIS trials appear
Sign up with your email to follow new studies for MYOSITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Long-Term control of rare muscle disease
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…
Matched conditions: MYOSITIS
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug aims to tame muscle inflammation in myositis
Disease control OngoingThis phase 2 trial tests whether nipocalimab, given intravenously, can improve symptoms of active idiopathic inflammatory myopathies (myositis) better than a placebo. About 36 adults with myositis will receive either nipocalimab or a placebo, along with standard steroid treatment…
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for myositis: early IVIg may boost recovery
Disease control OngoingThis study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…
Matched conditions: MYOSITIS
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Promising psoriasis drug study for rare muscle disease pulled before start
Disease control TerminatedThis study planned to test deucravacitinib, a drug already approved for psoriasis, in adults with hard-to-treat dermatomyositis (DM) or juvenile dermatomyositis (JDM). Participants would have taken a pill twice daily for 24 weeks, with clinic visits every 4 weeks. However, the st…
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug hopes to tame rare muscle and skin disease
Disease control OngoingThis study tests a drug called empasiprubart in adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Three participants receive either the drug or a placebo for 25 weeks, then are followed for 65 more weeks. The goal is to see if the drug is safe and…
Matched conditions: MYOSITIS
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused TerminatedThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Matched conditions: MYOSITIS
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC